ArticleCureus2025
A Mycophenolic Acid Concentration-Time Curve (0-12 Hours) to Maintain Remission Without Recurrent Infection in C1q Nephropathy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minimally Invasive Therapeutic Drug Monitoring of Immunosuppressants in Children with Kidney Diseases: Validation of Fingerstick Sampling Using LC-MS/MS.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C1q nephropathy (C1qN) presenting with steroid-resistant nephrotic syndrome (SRNS) often demands immunosuppressants to maintain remission. Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is one of the immunosuppressants used. However, MMF increases susceptibility to infection, which can lead to severe complications in some cases. Therefore, the optimal blood concentration of MMF for C1qN remains undefined. A three-year-old boy presented with SRNS due to C1qN and was treated with prednisolone (PSL) and MMF at 720 mg/day, achieving remission. However, the patient developed BK virus viruria and experienced a relapse of nephrotic syndrome (NS) simultaneously. After the MMF dose was reduced to 600 mg/day, the patient entered sustained remission without recurrent infections. Ultimately, he was able to maintain remission with only 600 mg/day of MMF, without the need for steroids. During the second remission, the area under the MPA concentration-time curve from 0 to 12 hours (MPA-AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.